Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up is a paper indexed in PICO Portal from OpenAlex.
How many citations does Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up have?
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up has 410 citations in the OpenAlex counts PICO Portal stores.
When was Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up published?
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up has 2013 year in the PICO Portal index.
What is the open-access status of Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up?
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up has closed oa status in the PICO Portal index.
What is the DOI of Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up?
The DOI for Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up is on the source record.
What is the PMID of Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up?
The PMID for Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up is on the source record.
What is the OpenAlex record for Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up?
The OpenAlex for Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up is on the source record.